MedPath

MAPREG

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Phase 2
Active, not recruiting
Conditions
Depression
Interventions
Drug: Placebo
First Posted Date
2019-03-12
Last Posted Date
2024-09-30
Lead Sponsor
Mapreg
Target Recruit Count
110
Registration Number
NCT03870776
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

CHU Besançon, Besançon, France

🇫🇷

CHD Vendée, La Roche-sur-Yon, France

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath